Zinc and somato-sexual development of adolescents
Journal Title: Міжнародний ендокринологічний журнал - Year 2017, Vol 13, Issue 2
Abstract
Background. The study investigated the age changes of zinc (Zn) in pubertal boys and its changes in delayed growth and sexual development. The aim of the study was to expand existing concepts about the influence of Zn deficiency disorders on the physical and sexual development in adolescents. Materials and methods. In 70 adolescent boys aged 10–17 years Zn level was evaluated, taking into account somato-sexual development and the presence of diffuse nontoxic goiter (DNG). Teens were divided into groups: 1) 20 boys aged 10–17 years with normal volume of the thyroid gland, normal physical and sexual development; 2) 17 adolescents aged 14–17 years with normal sexual development and DNG; 3) 15 adolescents aged 14–17 years with sexual development delay (SDD) and normal thyroid volume; 4) 18 adolescents aged 14–17 years with SDD and DNG. Results. The highest values of Zn were determined during the physiological puberty by itself within its physiologic course ((16.52; 14.27–18.66) mmol/l), which is significantly more than in the pre- ((13.53; 12.77–16.41) mmol/l; p < 0.05) and late puberty ((12.59; 10.22–16.07) mmol/l; p < 0.05). The adolescents with SDD ((14.41; 12.67–15.83) mmol/l) and short stature ((12.53; 8.80–15.46) mmol/l) had decreased Zn level, especially in the case of DNG ((10.03; 8.51–13.76) mmol/l). Regression and factor analysis studied the nature of the relationship between anthropometric indices, the degree of development of secondary sexual characteristics and Zn, functional state of the thyroid and reproductive systems. Conclusions. During puberty period Zn rates varies achieving its maximum level during the puberty by itself. Delayed growth and sexual development are associated with reduced Zn concentration in blood. The lowest Zn value is typical for the adolescents with DNG and SDD. There was grounded the necessity of Zincite drug application as a monotherapy or included into the complex treatment for the secondary prevention and treatment of Zn deficiency.
Authors and Affiliations
S. I. Turchina
Keywords
Related Articles
- EP ID EP176278
- DOI 10.22141/2224-0721.13.2.2017.100601
- Views 80
- Downloads 0
Effect of Pro197Leu Polymorphism of the Gene GPX1 on Carbohydrate Metabolism and Anthropometric Indices of Patients with Arterial Hypertension Against the Background of Abdominal Obesity
The aim of our study was to investigate the dependence of carbohydrate metabolism in patients with arterial hypertension and concomitant abdominal obesity depending on Pro197Leu polymorphism of the GPX1 gene. Pro197Leu p...
Incidence of Thyroid Structural Disorders in Patients with Type 2 Diabetes Mellitus
To study the incidence of structural changes of the thyroid gland (TG) in patients with diabetes mellitus (DM) type 2, we have examined 145 patients (75 patients with type 2 DM and obesity, 35 — with DM type 2 without ob...
Child’s Intellect and Iodine Deficiency: Mechanisms of Negative Impact and Ways of Prevention
The paper presents a review of scientific literature on the effect of iodine deficiency on the intellectual development of the child. The conclusion was made about the need for a mass iodine prophylaxis in the population...
Results of Epidemiological Surveys of Iodine Deficiency Disorders Prevalence in Fergana Region of Republic of Uzbekistan
In spite of extant programs aimed to liquidation of iodine deficiency, Republic of Uzbekistan still remains the zone of high prevalence of iodine deficiency disorders (IDD). Due to epidemiological surveys it has been def...
The Results of Open-Label, Multicenter, Non-Randomized Study on the Efficacy and Safety of Insulins: Insuman Basal®, Insuman Comb 25®, Insuman Rapid® in Patients with Diabetes Mellitus Type 2 Who Underwent Basic Training in Diabetes Schools (SPIRIT)
The objective of this study was to evaluate the level of glycated hemoglobin (HbA1c) reduction after 6 months of treatment with Insuman® insulin in patients with diabetes mellitus type 2 (DM-2), who were not treated with...